Aptevo Seeks Stockholder Approval for 5.58M Warrant Shares and 180K New Equity Plan Shares

summarizeSummary

Aptevo's proxy seeks approval for 5.58M warrant shares from its recent $4.5M financing and 180K new equity plan shares. Approval would unlock the warrants at $4.03, far above the current $2.68 price, but failure could hamper future fundraising.

check_boxKey Events · Financing and Capital Events · APVO

• Warrant Share Approval Sought

  Proposal 2 asks stockholders to approve issuance of 5,583,150 shares underlying Inducement Warrants and Common Warrants from the August 12 financing, exceeding Nasdaq's 20% threshold.

• Massive Potential Dilution

  If all warrants are exercised, 6,444,858 shares would be issued, more than tripling the current 1.8 million outstanding shares. Exercise price is $4.03, above the current $2.68 stock price.

• Equity Plan Expansion

  Proposal 3 requests 180,000 additional shares for the Fifth Amended and Restated 2018 Stock Incentive Plan, bringing total available to 332,360 shares.

• Non-Approval Consequences

  If Proposal 2 fails, the warrants become worthless and the company must call a stockholder meeting every 60 days until approval, potentially discouraging future investors.

auto_awesomeAnalysis · APVO · Life Sciences

Aptevo is asking shareholders to approve the issuance of 5,583,150 shares underlying warrants from its August 12 financing, which would exceed 19.99% of outstanding shares and trigger Nasdaq's 20% rule. If approved, the warrants become exercisable at $4.03 per share, potentially adding over 300% to the current share count of 1.8 million. The company also seeks 180,000 new shares for its equity incentive plan. Failure to approve would leave the warrants worthless and force the company to call a meeting every 60 days, signaling potential difficulty raising future capital. The stock trades near its 52-week low of $2.58, well below the $4.03 exercise price, making the warrants currently out-of-the-money but still a significant overhang.